查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086123

眼科藥品市場：2026-2032年全球市場預測（依產品類型、藥物類別、給藥途徑、治療領域、病患群體、最終使用者和通路分類）

Ophthalmic Drugs Market by Product Type, Drug Class, Route of Administration, Therapeutic Area, Patient Demographics, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，眼科藥品市場將成長至 777.2 億美元，複合年成長率為 9.16%。

主要市場統計數據
基準年 2025 420.6億美元
預計年份：2026年 458.6億美元
預測年份 2032 777.2億美元
複合年成長率 (%) 9.16%

眼科藥品市場概覽

隨著眼科護理從一次性治療轉向長期疾病管理，眼科藥品市場正在不斷擴張，這些疾病包括青光眼、乾眼症、視網膜疾病、眼部發炎、過敏、感染疾病以及罕見遺傳性眼科疾病。人口老化、糖尿病盛行率上升、螢幕使用時間延長以及慢性眼表和視網膜疾病診斷範圍的擴大，都推動了這項需求的成長。

眼科治療的變革性變化

眼科治療領域正因長效視網膜療法、無防腐劑製劑、緩釋製劑以及抗VEGF療法的生物相似藥的出現而改變。這些變革至關重要，因為患者依從性仍然是治療青光眼和乾眼症等慢性眼科疾病的一大挑戰，而患者是否堅持治療直接影響治療效果。

人工智慧（AI）的累積影響

人工智慧（AI）正日益成為眼科藥物研發、診斷和病患監測等各環節的強大驅動力。一項獲得FDA批准的用於糖尿病視網膜病變篩檢的自主AI系統已證實了演算法驅動型眼科診療的臨床有效性。此外，AI影像分析正在改善視網膜疾病臨床試驗的合格標準、病變量化以及疾病進展追蹤。

關於眼科藥物的關鍵區域見解

亞太地區是眼科藥品市場最重要的成長引擎之一，這主要得益於不斷成長的老齡人口、日益沉重的糖尿病負擔，以及中國、印度、日本、韓國、澳洲等東協國家眼科專科醫療服務的普及。國際糖尿病聯盟（IDF）已將亞洲列為糖尿病負擔尤為沉重的關鍵地區，導致對糖尿病視網膜篩檢和治療的需求不斷成長。日本和澳洲正在引進高附加價值的創新視網膜疾病和青光眼治療藥物，而中國和印度則見證了品牌學名藥、生物相似藥和價格適中的慢性眼科疾病治療藥物市場的成長。

領先集團對全球合作關係的洞察

在東協市場，都市化、糖尿病盛行率上升以及醫療保健投資的增加，推動了對易於取得的眼科藥物的需求和重視程度不斷提高，尤其是在治療青光眼、感染疾病、過敏、乾眼症和糖尿病眼部併發症。海灣合作理事會（GCC）國家正致力於提供高品質的專科護理、以醫院為基礎的眼科護理、引進創新療法，並透過公私合營提供一體化的醫療保健服務，所有這些都得到了國家醫療保健現代化計劃的支持。

主要國家眼科藥物分析

美國憑藉著專科醫生的積極處方、FDA的創新核准途徑、廣泛的視網膜診所網路以及注射式視網膜療法的廣泛應用，在全球眼科藥物商業化領域處於領先地位。加拿大強調循證報銷和公共及私人保險覆蓋範圍的協調，而墨西哥和巴西預計將會成長，這得益於私人醫療保健的擴張以及青光眼、乾眼症、眼部感染疾病、過敏和糖尿病眼科疾病等治療方案的增加。

為行業領導者提供的實用建議

產業領導者應優先開發差異化產品，以應對特定的臨床挑戰，例如延長給藥間隔、提高耐受性、提供不含遵守用藥的製劑、緩釋製劑以及提高真實臨床實踐中的依從性。商業性成功將越來越取決於能否證明產品的持續療效、對支付方的價值、安全性以及易於整合到眼科診療流程中。

調查方法

本執行摘要是透過對公開可檢驗資訊來源的二手研究和市場情報整合編製而成，這些來源包括監管公告、公共衛生數據、臨床指南趨勢、同行評審文獻、醫療保健政策參​​考資料、疾病負擔資料庫以及眼科治療路徑審查。

結論

眼科藥品市場正進入一個更專業化的階段，其特點是生物製藥、生物相似藥、緩釋製劑平台、人工智慧診斷技術以及針對視網膜和眼表疾病的精準醫療方法。人口老化、糖尿病、數位化生活方式的普及以及全球可預防性視力障礙帶來的沉重負擔，持續支撐著市場需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 眼科藥品市場：依產品類型分類

  • 非處方藥
  • 處方藥

第8章 眼科藥物市場：依藥物類別分類

  • 抗過敏藥物
    • 抗組織胺藥
    • 肥大細胞穩定劑
  • 青光眼治療藥物
    • α-腎上腺素促效劑
    • BETA受體阻斷劑
    • 碳酸酐酶抑制劑
    • 前列腺素類似物
  • 抗發炎藥
    • 皮質類固醇
    • 非類固醇消炎劑（NSAIDs）
  • 抗 VEGF 藥物
    • 阿柏西普
    • 布羅盧西珠單抗
    • 雷尼珠單抗
  • 抗生素
    • Aminoglycosides抗生素
    • Fluoroquinolones
    • 大環內酯類
    • 四環黴素
  • 抗真菌藥物
  • 抗病毒藥物
    • 阿昔洛韋
    • 更昔洛韋
    • 離胺酸
    • 伐昔洛韋

第9章：眼科藥物市場：依給藥途徑分類

  • 注射藥物
    • 前房注射
    • 玻璃體內注射
  • 口服
    • 膠囊
    • 藥片
  • 外用
    • 眼藥水
    • 凝膠
    • 軟膏

第10章：眼科藥品市場：依治療領域分類

  • 老齡化黃斑部病變（AMD）
    • 乾性酸性礦山排水
    • 濕性AMD
  • 白內障
  • 結膜炎
  • 糖尿病視網膜病變
  • 乾眼症
  • 青光眼
  • 眼部感染疾病

第11章 眼科藥物市場：依患者群體分類

  • 成人
  • 老年人
  • 兒童

第12章：眼科藥品市場：依最終用戶分類

  • 門診手術中心
  • 居家醫療
  • 醫院
  • 眼科診所

第13章：眼科藥品市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 眼科藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：眼科藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 眼科藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc.
  • Ajanta Pharma Ltd.
  • Alcon Vision LLC
  • Apotex Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • Cipla Limited
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Service, Inc.
  • KODIAK SCIENCES INC.
  • Lotus Pharmaceuticals
  • Lupin Limited
  • Merck & Co., Inc.
  • Nicox SA
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • OCuSOFT Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Outlook Therapeutics, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co.,Ltd.
  • Somerset Pharma, LLC.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-036C5CF3A8ED

The Ophthalmic Drugs Market is projected to grow by USD 77.72 billion at a CAGR of 9.16% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 42.06 billion
Estimated Year [2026] USD 45.86 billion
Forecast Year [2032] USD 77.72 billion
CAGR (%) 9.16%

Ophthalmic Drugs Market Introduction

The ophthalmic drugs market is expanding as vision care shifts from episodic treatment to long-term disease management across glaucoma, dry eye disease, retinal disorders, ocular inflammation, allergy, infection, and rare inherited eye diseases. Demand is supported by population aging, diabetes prevalence, high screen exposure, and broader diagnosis of chronic ocular surface and retinal conditions.

Public health agencies continue to underscore the scale of need: the World Health Organization reports that at least 2.2 billion people live with near or distance vision impairment, and at least 1 billion cases could have been prevented or remain unaddressed. This creates sustained demand for prescription eye drops, anti-VEGF injections, corticosteroids, immunomodulators, antibiotics, biologics, biosimilars, and emerging gene and cell therapies.

Transformative Shifts in Ophthalmic Therapeutics

The ophthalmic therapeutics landscape is being reshaped by longer-acting retinal therapies, preservative-free formulations, sustained-release delivery, and biosimilar competition in anti-VEGF treatment. These shifts are important because adherence remains a major challenge in chronic eye diseases such as glaucoma and dry eye disease, where patient persistence directly affects outcomes.

Regulators are also widening the innovation pathway for specialty ophthalmology. Recent approvals in geographic atrophy, dry eye disease, inherited retinal disease, and biosimilar ranibizumab demonstrate a market moving beyond traditional topical therapy toward targeted biologics, complement inhibition, and precision medicine.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across ophthalmic drug development, diagnosis, and patient monitoring. FDA-cleared autonomous AI for diabetic retinopathy screening has validated the clinical relevance of algorithm-supported eye care, while AI-assisted image analysis is improving trial eligibility, lesion quantification, and disease progression tracking in retinal disorders.

For ophthalmic drug manufacturers, AI can reduce operational friction by improving patient identification, optimizing clinical trial site selection, monitoring real-world safety signals, and supporting personalized adherence programs. The strongest commercial value is expected where AI is paired with retinal imaging, electronic health records, and connected care models.

Key Regional Insights for Ophthalmic Drugs

Asia-Pacific is one of the most important growth engines for ophthalmic drugs due to large aging populations, rising diabetes burden, and expanding access to specialty eye care in China, India, Japan, South Korea, Australia, and ASEAN markets. The International Diabetes Federation identifies Asia as a major center of diabetes burden, reinforcing demand for diabetic retinopathy screening and retinal therapies. Japan and Australia support high-value adoption of innovative retinal and glaucoma therapies, while China and India provide scale for branded generics, biosimilars, and affordable chronic eye disease treatment.

North America remains a premium innovation market, led by the United States' concentration of ophthalmology specialists, clinical trial activity, reimbursement infrastructure, and FDA approvals for novel retinal and ocular surface therapies. Europe combines strong regulatory standards with broad public health systems, making market access, pharmacoeconomic evidence, and country-level reimbursement negotiations central to uptake across glaucoma, age-related macular degeneration, dry eye disease, and inflammatory eye disorders.

Latin America is advancing through expanding private ophthalmology networks and demand for glaucoma, dry eye, infection, and retinal disease therapies, with Brazil and Mexico serving as important commercial anchors. The Middle East, particularly GCC countries, is investing in specialty healthcare infrastructure and tertiary eye hospitals, while Africa's opportunity is shaped by access expansion, essential medicines availability, workforce capacity, and preventable blindness programs supported by global eye health initiatives.

Key Group Insights Across Global Alliances

ASEAN markets are gaining relevance as urbanization, diabetes prevalence, and healthcare investment increase demand for accessible ophthalmic drugs, particularly for glaucoma, infection, allergy, dry eye disease, and diabetic eye complications. GCC countries are more focused on premium specialty care, hospital-based ophthalmology, imported innovative therapies, and integrated public-private healthcare delivery supported by national healthcare modernization programs.

The European Union represents a highly regulated but commercially significant bloc where centralized and national regulatory processes, health technology assessment, and reimbursement rules shape adoption. BRICS markets combine high patient volume with increasing domestic pharmaceutical manufacturing and biosimilar capacity, making pricing strategy, local evidence generation, and regional partnerships essential for sustainable access.

G7 countries remain central to ophthalmic drug innovation, regulatory precedent, clinical guideline development, and premium therapy adoption, particularly in the United States, Japan, Germany, France, Italy, the United Kingdom, and Canada. NATO-aligned markets broadly benefit from mature procurement systems, established pharmacovigilance frameworks, and high clinical standards, although reimbursement timing, prescribing restrictions, and formulary access vary widely.

Key Country Insights in Ophthalmic Drugs

The United States leads global commercialization for ophthalmic drugs through strong specialty prescribing, FDA innovation pathways, extensive retina clinic networks, and high use of injectable retinal therapies. Canada emphasizes evidence-based reimbursement and public-private coverage coordination, while Mexico and Brazil provide growth through expanding private care and rising treatment of glaucoma, dry eye, ocular infection, allergy, and diabetic eye disease.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine large aging populations with structured reimbursement systems, making health economics, comparative effectiveness, and real-world evidence critical for market access. Russia remains a distinct market shaped by localization, affordability, public procurement, and access to essential ophthalmic medicines for chronic and infectious eye conditions.

China and India are high-scale markets driven by diabetes, myopia, cataract-related care pathways, and local manufacturing capacity for generics and biosimilars. Japan supports advanced ophthalmic innovation and high clinical adoption, South Korea combines technology-led care with strong specialty access and retinal imaging utilization, and Australia maintains a mature reimbursement environment for high-value ophthalmology therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated assets that solve clear clinical problems, including longer dosing intervals, improved tolerability, preservative-free delivery, sustained-release formats, and stronger real-world adherence. Commercial success will increasingly depend on demonstrating durable outcomes, payer value, safety, and ease of integration into ophthalmology workflows.

Companies should strengthen regional evidence strategies, expand partnerships with retina, glaucoma, cornea, and ocular surface specialists, and use AI-enabled screening or monitoring to improve patient identification. Manufacturers also need resilient supply chains, biosimilar defense strategies, pharmacovigilance readiness, and access models tailored to mature, emerging, and essential-medicine markets.

Research Methodology

This executive summary is developed through secondary research and market intelligence synthesis using publicly available and verifiable sources, including regulatory agency communications, public health data, clinical guideline trends, peer-reviewed literature, healthcare policy references, disease burden databases, and ophthalmology treatment pathway reviews.

The analysis applies triangulation across disease burden, product innovation, regulatory activity, reimbursement dynamics, regional healthcare infrastructure, access conditions, and competitive positioning. Insights are validated for consistency with known ophthalmology treatment pathways, current industry developments, and documented public health priorities, while excluding market sizing, market share, and forecasting assumptions.

Conclusion

The ophthalmic drugs market is entering a more specialized phase defined by biologics, biosimilars, sustained-release platforms, AI-enabled diagnostics, and precision approaches for retinal and ocular surface diseases. Demand remains structurally supported by aging, diabetes, digital lifestyle exposure, and the global burden of preventable vision impairment.

Companies that align clinical differentiation with affordability, evidence generation, and regional access strategies will be best positioned to strengthen competitiveness. The most successful participants will combine therapeutic innovation with delivery convenience, data-driven patient identification, robust safety monitoring, and strong payer-relevant outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Ophthalmic Drugs Market, by Product Type

  • 7.1. Over-The-Counter Drugs
  • 7.2. Prescription Drugs

8. Ophthalmic Drugs Market, by Drug Class

  • 8.1. Anti-Allergics
    • 8.1.1. Antihistamines
    • 8.1.2. Mast Cell Stabilizers
  • 8.2. Anti-Glaucoma Agents
    • 8.2.1. Alpha-Adrenergic Agonists
    • 8.2.2. Beta-Blockers
    • 8.2.3. Carbonic Anhydrase Inhibitors
    • 8.2.4. Prostaglandin Analogs
  • 8.3. Anti-Inflammatories
    • 8.3.1. Corticosteroids
    • 8.3.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
  • 8.4. Anti-VEGF Agents
    • 8.4.1. Aflibercept
    • 8.4.2. Brolucizumab
    • 8.4.3. Ranibizumab
  • 8.5. Antibiotics
    • 8.5.1. Aminoglycosides
    • 8.5.2. Fluoroquinolones
    • 8.5.3. Macrolides
    • 8.5.4. Tetracyclines
  • 8.6. Antifungal
  • 8.7. Antiviral
    • 8.7.1. Acyclovir
    • 8.7.2. Ganciclovir
    • 8.7.3. Trifluridine
    • 8.7.4. Valaciclovir

9. Ophthalmic Drugs Market, by Route of Administration

  • 9.1. Injectable
    • 9.1.1. Intracameral injection
    • 9.1.2. Intravitreal Injections
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Tablets
  • 9.3. Topical
    • 9.3.1. Eye Drops
    • 9.3.2. Gels
    • 9.3.3. Ointments

10. Ophthalmic Drugs Market, by Therapeutic Area

  • 10.1. Age Related Macular Degeneration (AMD)
    • 10.1.1. Dry AMD
    • 10.1.2. Wet AMD
  • 10.2. Cataracts
  • 10.3. Conjunctivitis
  • 10.4. Diabetic Retinopathy
  • 10.5. Dry Eye Syndrome
  • 10.6. Glaucoma
  • 10.7. Ocular Infections

11. Ophthalmic Drugs Market, by Patient Demographics

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Ophthalmic Drugs Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Home Care Settings
  • 12.3. Hospitals
  • 12.4. Ophthalmic Clinics

13. Ophthalmic Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Ophthalmic Drugs Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Ophthalmic Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Ophthalmic Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc.
  • 18.2. Ajanta Pharma Ltd.
  • 18.3. Alcon Vision LLC
  • 18.4. Apotex Inc.
  • 18.5. Bausch Health Companies Inc.
  • 18.6. Bayer AG
  • 18.7. Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • 18.8. Cipla Limited
  • 18.9. EyePoint Pharmaceuticals, Inc.
  • 18.10. F. Hoffmann-La Roche Ltd
  • 18.11. Intas Pharmaceuticals Ltd.
  • 18.12. Johnson & Johnson Service, Inc.
  • 18.13. KODIAK SCIENCES INC.
  • 18.14. Lotus Pharmaceuticals
  • 18.15. Lupin Limited
  • 18.16. Merck & Co., Inc.
  • 18.17. Nicox SA
  • 18.18. Novartis AG
  • 18.19. Ocular Therapeutix, Inc.
  • 18.20. OCuSOFT Inc.
  • 18.21. Otsuka Pharmaceutical Co., Ltd.
  • 18.22. Outlook Therapeutics, Inc.
  • 18.23. Pfizer Inc.
  • 18.24. Regeneron Pharmaceuticals Inc.
  • 18.25. Santen Pharmaceutical Co., Ltd.
  • 18.26. Senju Pharmaceutical Co.,Ltd.
  • 18.27. Somerset Pharma, LLC.
  • 18.28. Sun Pharmaceutical Industries Ltd.
  • 18.29. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPHTHALMIC DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL OPHTHALMIC DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL OPHTHALMIC DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL OPHTHALMIC DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-ALLERGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-ALLERGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-ALLERGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIHISTAMINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIHISTAMINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIHISTAMINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MAST CELL STABILIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MAST CELL STABILIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MAST CELL STABILIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-GLAUCOMA AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-GLAUCOMA AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-GLAUCOMA AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ALPHA-ADRENERGIC AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALPHA-ADRENERGIC AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ALPHA-ADRENERGIC AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BETA-BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BETA-BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BETA-BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTAGLANDIN ANALOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROSTAGLANDIN ANALOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTAGLANDIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFLAMMATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFLAMMATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFLAMMATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AFLIBERCEPT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AFLIBERCEPT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AFLIBERCEPT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BROLUCIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BROLUCIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BROLUCIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RANIBIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RANIBIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RANIBIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MACROLIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MACROLIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MACROLIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TETRACYCLINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TETRACYCLINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TETRACYCLINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIFUNGAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIFUNGAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIFUNGAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACYCLOVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACYCLOVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ACYCLOVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GANCICLOVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GANCICLOVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GANCICLOVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TRIFLURIDINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRIFLURIDINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TRIFLURIDINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VALACICLOVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VALACICLOVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VALACICLOVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INTRACAMERAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRACAMERAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INTRACAMERAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRAVITREAL INJECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INTRAVITREAL INJECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRAVITREAL INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL EYE DROPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL EYE DROPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL EYE DROPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL OINTMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL OINTMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL OINTMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRY AMD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DRY AMD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRY AMD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL WET AMD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL WET AMD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL WET AMD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CATARACTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CATARACTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CATARACTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CONJUNCTIVITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CONJUNCTIVITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CONJUNCTIVITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GLAUCOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GLAUCOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL OCULAR INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL OCULAR INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL OCULAR INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL OPHTHALMIC CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL OPHTHALMIC CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL OPHTHALMIC CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. GCC OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. GCC OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. GCC OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 311. GCC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2018-2032 (USD MILLION)
  • TABLE 312. GCC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2018-2032 (USD MILLION)
  • TABLE 313. GCC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 314. GCC OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 315. GCC OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 316. GCC OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 317. GCC OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. GCC OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 319. GCC OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 320. GCC OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 321. GCC OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 322. GCC OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2018-2032 (USD MILLION)
  • TABLE 323. GCC OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 324. GCC OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. GCC OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 326. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2018-2032 (USD MILLION)
  • TABLE 330. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2018-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 332. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 334. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 336. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 338. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 340. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2018-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 342. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. EUROPEAN UNION OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 344. BRICS OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 347. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2018-2032 (USD MILLION)
  • TABLE 348. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2018-2032 (USD MILLION)
  • TABLE 349. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 350. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 351. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 352. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 353. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 354. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 355. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 356. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 357. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 358. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION (AMD), 2018-2032 (USD MILLION)
  • TABLE 359. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 360. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 361. BRICS OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 362. G7 OPHTHALMIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 363. G7 OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 364. G7 OPHTHALMIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 365. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-ALLERGICS, 2018-2032 (USD MILLION)
  • TABLE 366. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-GLAUCOMA AGENTS, 2018-2032 (USD MILLION)
  • TABLE 367. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 368. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 369. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 370. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ANTIVIRAL, 2018-2032 (USD MILLION)
  • TABLE 371. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 372. G7 OPHTHALMIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 373. G7 OPHTHALMIC DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 374. G7 OPHTHALMIC DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 375. G7 OPHTHALM